Evidence map›Paper›PMID 36291784›Full record

ArticleCancers2022

Oligometastatic Breast Cancer Patients Treated with High-Dose Chemotherapy and Targeted Radiation: Long-Term Follow-Up of a Phase II Trial.

Colton Ladbury, Claire Hao, Christopher Ruel, Jason Liu, Scott Glaser, Arya Amini, Jeffrey Wong, Isaac Paz, Lucille Leong, Robert Morgan and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Colton LadburyDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.ORCID 0000-0002-2668-3415
Claire HaoDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
Christopher RuelDivision of Biostatistics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Jason LiuDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.ORCID 0000-0003-2287-2320
Scott GlaserDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
Arya AminiDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
Jeffrey WongDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
Isaac PazDepartment of Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA.
Lucille LeongDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA.
Robert MorganDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA.
Kim MargolinDepartment of Medical Oncology, Saint John's Cancer Institute, Santa Monica, CA 90404, USA.
Stephen ShibataDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA.
Paul FrankelDivision of Biostatistics, City of Hope National Medical Center, Duarte, CA 91010, USA.
George SomloDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA.
Savita DandapaniDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
City Of Hope National Medical Center · USSaint John's Health Center · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572NCI NIH HHS P30CA033572
6 · The paper itself

Abstract

backgroundPatients with oligometastatic breast cancer (oMBC) may benefit from aggressive local therapy. We sought to assess the effects of consolidative radiation therapy (RT) on outcomes in oMBC patients treated on a prospective phase II trial of high-dose chemotherapy (HDCT).

methodsBetween 2005 and 2009, 12 patients with oMBC (≤3 metastatic sites) cancer were treated on protocol. Patients were to receive tandem HDCT supported by hematopoietic cell rescue (HCR). All radiographically identifiable oligometastatic sites received targeted radiation.

resultsHDCT was initiated at a median of 6.7 (3.5-12.7) months after diagnosis of oMBC. Hormone receptors (HR) were positive in 91.6% of patients, and HER2 was overexpressed in 25% of patients. Median radiation dose (EQD2) was 41.2 (37.9-48.7) Gy. Median follow-up was 13.1 (6.8-15.1) years for living patients. Ten-year PFS and OS were 33% (95%CI, 10-59%) and 55% (95%CI, 22-79%), respectively. Durable local control of treated lesions was 87.5%. At the last follow up, two patients remained progression free and two more were without evidence of disease following additional salvage treatment.

conclusionsAlthough modern systemic therapies have obviated the use of HDC, aggressive local therapy warrants further evaluation and fractionated radiotherapy is a viable alternative if SBRT is not available.

Indexed as

breast cancerhigh-dose chemotherapyoligometastasesradiation

Identifiers

PMID36291784
PMCPMC9599732
OpenAlexW4306149841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.